Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer

Chee K. Lee, Michael Friedlander, Chris Brown, Val J. Gebski, Alexander Georgoulopoulos, Ignace Vergote, Sandro Pignata, Nicoletta Donadello, Barbara Schmalfeldt, Rémy Delva, Mansoor Raza Mirza, Philippe Sauthier, Eric Pujade-Lauraine, Sarah J. Lord, R. John Simes

Research output: Contribution to journalArticle

Abstract

We used data from 886 patients from the CAELYX in Platinum Sensitive Ovarian Patients (CALYPSO) trial, recruited between April 2005 and September 2007, to examine the role of early decline in cancer antigen 125 (CA125) and early tumor response as prognostic factors and surrogates for superiority of treatment with carboplatin-pegylated liposomal doxorubicin (CPLD) compared with carboplatin-paclitaxel (CP) in a landmark analysis. Progression-free survival (PFS) was estimated by Kaplan-Meier analyses. We used univariate and multivariable Cox proportional hazards analyses to assess early decline and early response as surrogates for CPLD treatment benefit compared with CP. All statistical tests were two-sided. Early decline (defined as rate of CA125 decrease of at least 50% per month) was associated with improved PFS (adjusted hazard ratio [HR] for progression = 0.81, 95% confidence interval [CI] = 0.67 to 0.97, P =. 02) but early response (complete or partial responses) was not. CPLD was associated with improved PFS compared with CP (HR = 0.82, 95% CI = 0.69 to 0.96, P =. 01). However, fewer CPLD patients had an early decline (161 [37.4%] vs 233 [51.2%], P

Original languageEnglish
Pages (from-to)1338-1342
Number of pages5
JournalJournal of the National Cancer Institute
Volume103
Issue number17
DOIs
Publication statusPublished - Sep 7 2011

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Lee, C. K., Friedlander, M., Brown, C., Gebski, V. J., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Mirza, M. R., Sauthier, P., Pujade-Lauraine, E., Lord, S. J., & Simes, R. J. (2011). Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. Journal of the National Cancer Institute, 103(17), 1338-1342. https://doi.org/10.1093/jnci/djr282